Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease

A previously published clinical trial demonstrated the benefit of autologous CD34(+) cells transduced with a self-inactivating lentiviral vector (HPV569) containing an engineered β-globin gene (β(A-T87Q)-globin) in a subject with β-thalassemia major. This vector has been modified to increase transdu...

Descripción completa

Detalles Bibliográficos
Autores principales: Negre, Olivier, Bartholomae, Cynthia, Beuzard, Yves, Cavazzana, Marina, Christiansen, Lauryn, Courne, Céline, Deichmann, Annette, Denaro, Maria, de Dreuzy, Edouard, Finer, Mitchell, Fronza, Raffaele, Gillet-Legrand, Béatrix, Joubert, Christophe, Kutner, Robert, Leboulch, Philippe, Maouche, Leïla, Paulard, Anaïs, Pierciey, Francis J., Rothe, Michael, Ryu, Byoung, Schmidt, Manfred, von Kalle, Christof, Payen, Emmanuel, Veres, Gabor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440358/
https://www.ncbi.nlm.nih.gov/pubmed/25429463
http://dx.doi.org/10.2174/1566523214666141127095336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440358/
https://www.ncbi.nlm.nih.gov/pubmed/25429463
http://dx.doi.org/10.2174/1566523214666141127095336

Ejemplares similares